Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, has announced the approval of equity inducement grants for seven new non-officer employees. The grants, approved by the company's Compensation Committee, consist of 53,550 share options with an exercise price of $29.04 per common share, reflecting the closing price on May 29, 2025. These options are part of the company's 2025 Inducement Equity Incentive Plan and will vest over four years: 25% on the first anniversary of the employee's start date, with the remainder vesting monthly over the subsequent three years. The options have a 10-year term.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.